Singapore - engelsk - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - carbamazepine - tablet, film coated - 200 mg - carbamazepine 200 mg

Singapore - engelsk - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - carbamazepine - tablet, film coated - 400 mg - carbamazepine 400 mg

Singapore - engelsk - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - carbamazepine - suspension - 2 g/100 ml - carbamazepine 2 g/100 ml

USA - engelsk - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - carbamazepine (unii: 33cm23913m) (carbamazepine - unii:33cm23913m) - carbamazepine 100 mg in 5 ml - tegretol is indicated for use as an anticonvulsant drug. evidence supporting efficacy of tegretol as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: - partial seizures with complex symptomatology (psychomotor, temporal lobe). patients with these seizures appear to show greater improvement than those with other types. - generalized tonic-clonic seizures (grand mal). - mixed seizure patterns which include the above, or other partial or generalized seizures. absence seizures (petit mal) do not appear to be controlled by tegretol (see precautions, general). tegretol is indicated in the treatment of the pain associated with true trigeminal neuralgia. beneficial results have also been reported in glossopharyngeal neuralgia. this drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. tegretol should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug,

USA - engelsk - NLM (National Library of Medicine)

remedyrepack inc. - carbamazepine (unii: 33cm23913m) (carbamazepine - unii:33cm23913m) - tegretol is indicated for use as an anticonvulsant drug. evidence supporting efficacy of tegretol as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: - partial seizures with complex symptomatology (psychomotor, temporal lobe). patients with these seizures appear to show greater improvement than those with other types. - generalized tonic-clonic seizures (grand mal). - mixed seizure patterns which include the above, or other partial or generalized seizures. absence seizures (petit mal) do not appear to be controlled by tegretol (see precautions, general). tegretol is indicated in the treatment of the pain associated with true trigeminal neuralgia. beneficial results have also been reported in glossopharyngeal neuralgia. this drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. tegretol should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug,

Sveits - fransk - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - carbamazepinum - comprimés - carbamazepinum 200 mg, cellulosum microcristallinum, carmellosum natricum corresp. natrium < 23 mg, magnesii stearas, silica colloidalis anhydrica pro compresso. - antiepilepticum - synthetika

Sveits - fransk - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - carbamazepinum - comprimés - carbamazepinum 400 mg, cellulosum microcristallinum, carmellosum natricum corresp. natrium < 23 mg, magnesii stearas, silica colloidalis anhydrica pro compresso. - antiepilepticum - synthetika

Sveits - fransk - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - carbamazepinum - comprimés - carbamazepinum 100 mg, cellulosum microcristallinum, carmellosum natricum corresp. natrium < 23 mg, magnesii stearas, silica colloidalis anhydrica pro compresso. - antiepilepticum - synthetika

Sveits - fransk - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - carbamazepinum - suspension buvable - carbamazepinum 100 mg, macrogoli 8 stearas typus i, hydroxyethylcellulosum, cellulosum microcristallinum, carmellosum natricum, sorbitolum liquidum non cristallisabile 1.25 g, propylenglycolum 125 mg, aqua purificata, aromatica (caramel), saccharinum natricum, e 200, propylis parahydroxybenzoas 1.5 mg, e 218 6 mg ad suspensionem pro 5 ml corresp. natrium 0.57 mg. - antiepilepticum - synthetika

Sveits - fransk - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - carbamazepinum - retardtabletten - carbamazepinum 400 mg, magnesii stearas, silica colloidalis anhydrica, ethylcellulosum, talcum, polyacrylatis dispersio 30 per centum, carmellosum natricum conexum corresp. natrium 3 mg, cellulosum microcristallinum, Überzug: macrogolglyceroli hydroxystearas 0.44 mg, talcum, hypromellosum, e 171, e 172 (flavum), e 172 (rubrum) pro compresso obducto. - antiepilepticum - synthetika